Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $146.8 million.

  • Silence Therapeutics' Liabilities and Shareholders Equity fell 3330.13% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.0 million, marking a year-over-year decrease of 1476.43%. This contributed to the annual value of $202.6 million for FY2024, which is 7401.43% up from last year.
  • Silence Therapeutics' Liabilities and Shareholders Equity amounted to $146.8 million in Q3 2025, which was down 3330.13% from $165.2 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Liabilities and Shareholders Equity ranged from a high of $246.6 million in Q1 2024 and a low of $105.0 million during Q2 2022
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $140.8 million (2021), whereas its average is $155.3 million.
  • Per our database at Business Quant, Silence Therapeutics' Liabilities and Shareholders Equity surged by 11503.32% in 2024 and then tumbled by 3330.13% in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Liabilities and Shareholders Equity stood at $129.7 million in 2021, then decreased by 2.76% to $126.1 million in 2022, then fell by 7.65% to $116.4 million in 2023, then surged by 74.01% to $202.6 million in 2024, then fell by 27.56% to $146.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $146.8 million in Q3 2025, compared to $165.2 million in Q2 2025 and $185.3 million in Q1 2025.